久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

DNA Link  
DNA Link, Inc (127120.KS)成立于2000年3月，總部位于韓國首爾，為一家遺傳學研究公司，主要從事基因分析工作，并致力于單一核苷酸多型性(SNP)的關聯研究。與DNA有關的慢性疾病，包括有糖尿病、心血管疾病、皮膚病(過敏體質)與消化系統疾病等，公司將針對人類的基因遺傳，作為疾病的早期診斷、治療及藥物的開發等。

DNA Link, Inc.
Established in March 2000, DNA Link is a biotechnology company specializing in SNP research and a leader in personalized genomics.

Collaborations With Korea’s Elite Clinical Researchers
DNA Link is currently in collaboration with Korea’s most renowned clinical research specialists studying genetic effects of various diseases including diabetes, cardiovascular disease, cancer, atopy, and digestive diseases.
Recent advancements in genomic research technology have enabled rapid analysis of whole genomes. Our current research projects utilize this technology to identify relationships between diseases and genomic content.

In the past, genetic disease studies were conducted using a finite set of candidate genes as targets for research. While the results were valuable, the success of this approach was limited because diseases can depend on multiple factors, genetic and environmental. Modern genetic research methodologies take a more extended approach, considering the entire human genome to search for potential disease markers.

In addition to identifying disease-related genes, DNA Link is working to develop disease diagnostic systems as well as personalized treatment methods. Using DNA Chip and Next Generation Sequencing technologies, we are currently developing cancer diagnostic systems by identifying common variants in DNA copy numbers for various cancers including lung cancer and breast cancer.
Laying the Foundation for Personalized Healthcare
At DNA Link, our mission is to lay the foundation for personalized healthcare and contribute to extending the human life expectancy. Through our research in discovering genetic disease precursors and variations in the human genome, we aim to develop a system for personalized disease prevention, early detection and treatment plans.